Ahmedabad-based Intas Pharmaceuticals has launched the cancer drug Bevacizumab at prices 60 per cent less than the currently available options.
On Wednesday, the company announced that its Bevacizumab therapy would cost Rs 39,995 for the dose strength of 400 mg variant, which makes it 60 per cent less than the currently available options.
It would bring relief to a large number of cancer patients in India for whom the drug was out of reach until now. The drug was available in India since 2004. However, the cost of therapy was high.
It is estimated that every year over 700,000 patients die due to